Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study - Concepedia

Concepedia

Publication | Open Access

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

DOI Full Paper Access

373

Citations

26

References

2019

Year

Steven W. Pipe, Midori Shima, Michaela Lehle, Amy D. Shapiro, Sammy Chebon, Katsuyuki Fukutake, Nigel S. Key, Agnès Portron, Christophe Schmitt, Maria Podolak‐Dawidziak,

The Lancet Haematology

Haven 4HematologyNon-randomised Phase 3Emicizumab ProphylaxisMedicine

References

	Year	Citations

Page 1